Ranbie Tang, Mengna Liu, Qiaoqiao Shu, Xi Chen, Liang Cai
{"title":"成纤维细胞活化蛋白抑制剂 PET 成像用于胰腺肿瘤评估的性能：系统综述和荟萃分析。","authors":"Ranbie Tang, Mengna Liu, Qiaoqiao Shu, Xi Chen, Liang Cai","doi":"10.1007/s00330-024-10843-z","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Recent studies have shown the potential of fibroblast activating protein inhibitor (FAPI) PET imaging for pancreatic cancer assessment.</p><p><strong>Purpose: </strong>This article is dedicated to comparing the diagnostic efficacy of FAPI PET and [<sup>18</sup>F]fluorodeoxyglucose (FDG) PET in the evaluation of primary tumors, lymph nodes, and distant metastases in pancreatic cancer.</p><p><strong>Methods: </strong>In this review, we conducted a systematic search of studies published in PubMed and Web of Science databases up to September 18, 2023. All included studies used radionuclide labeled FAPI and FDG as PET diagnostic tracers to evaluate their applicability in patients with pancreatic cancer.</p><p><strong>Results: </strong>The FAPI PET imaging group showed significantly higher sensitivity in the detection of primary lesions (1.000, [95% CI: 0.999-1.000]), lymph node metastases (0.624 [95% CI: 0.391-0.834]) and distant metastatic (0.965 [95% CI: 0.804-1.000]) in pancreatic cancer compared to the FDG PET imaging group (0.889 [95% CI: 0.788-0.966], 0.373 [95% CI: 0.163-0.606] and 0.889 [95% CI: 0.689-0.999], respectively). Furthermore, the maximum standardized uptake value (SUVmax) in FAPI PET imaging is significantly higher than that in FDG imaging for primary lesions (mean difference (MD) = 7.51, 95% CI: 5.34-9.67).</p><p><strong>Conclusion: </strong>Compared with [<sup>18</sup>F]FDG PET/CT, FAPI PET imaging showed higher sensitivity, SUVmax. This method can be effectively utilized for the evaluation of pancreatic cancer.</p><p><strong>Clinical relevance statement: </strong>Fibroblast activating protein inhibitor PET may be a better alternative to [<sup>18</sup>F]FDG in evaluating primary pancreatic cancer, lymph node metastases, and distant metastases.</p><p><strong>Key points: </strong>Fibroblast activating protein inhibitor (FAPI) PET is compared with FDG PET for evaluating pancreatic cancer. Multiple radiolabeled FAPI variants have shown promising results in the diagnosis of pancreatic cancer. FAPI PET imaging effectively helps clinicians diagnose and stage pancreatic cancer.</p>","PeriodicalId":12076,"journal":{"name":"European Radiology","volume":" ","pages":"7804-7812"},"PeriodicalIF":4.7000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Performance of fibroblast activating protein inhibitor PET imaging for pancreatic neoplasms assessment: a systematic review and meta-analysis.\",\"authors\":\"Ranbie Tang, Mengna Liu, Qiaoqiao Shu, Xi Chen, Liang Cai\",\"doi\":\"10.1007/s00330-024-10843-z\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Recent studies have shown the potential of fibroblast activating protein inhibitor (FAPI) PET imaging for pancreatic cancer assessment.</p><p><strong>Purpose: </strong>This article is dedicated to comparing the diagnostic efficacy of FAPI PET and [<sup>18</sup>F]fluorodeoxyglucose (FDG) PET in the evaluation of primary tumors, lymph nodes, and distant metastases in pancreatic cancer.</p><p><strong>Methods: </strong>In this review, we conducted a systematic search of studies published in PubMed and Web of Science databases up to September 18, 2023. All included studies used radionuclide labeled FAPI and FDG as PET diagnostic tracers to evaluate their applicability in patients with pancreatic cancer.</p><p><strong>Results: </strong>The FAPI PET imaging group showed significantly higher sensitivity in the detection of primary lesions (1.000, [95% CI: 0.999-1.000]), lymph node metastases (0.624 [95% CI: 0.391-0.834]) and distant metastatic (0.965 [95% CI: 0.804-1.000]) in pancreatic cancer compared to the FDG PET imaging group (0.889 [95% CI: 0.788-0.966], 0.373 [95% CI: 0.163-0.606] and 0.889 [95% CI: 0.689-0.999], respectively). Furthermore, the maximum standardized uptake value (SUVmax) in FAPI PET imaging is significantly higher than that in FDG imaging for primary lesions (mean difference (MD) = 7.51, 95% CI: 5.34-9.67).</p><p><strong>Conclusion: </strong>Compared with [<sup>18</sup>F]FDG PET/CT, FAPI PET imaging showed higher sensitivity, SUVmax. This method can be effectively utilized for the evaluation of pancreatic cancer.</p><p><strong>Clinical relevance statement: </strong>Fibroblast activating protein inhibitor PET may be a better alternative to [<sup>18</sup>F]FDG in evaluating primary pancreatic cancer, lymph node metastases, and distant metastases.</p><p><strong>Key points: </strong>Fibroblast activating protein inhibitor (FAPI) PET is compared with FDG PET for evaluating pancreatic cancer. Multiple radiolabeled FAPI variants have shown promising results in the diagnosis of pancreatic cancer. FAPI PET imaging effectively helps clinicians diagnose and stage pancreatic cancer.</p>\",\"PeriodicalId\":12076,\"journal\":{\"name\":\"European Radiology\",\"volume\":\" \",\"pages\":\"7804-7812\"},\"PeriodicalIF\":4.7000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"European Radiology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s00330-024-10843-z\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/6/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q1\",\"JCRName\":\"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Radiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s00330-024-10843-z","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/21 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0
摘要
背景：最近的研究表明，成纤维细胞活化蛋白抑制剂（FAPI）PET成像在胰腺癌评估中具有潜力：目的：本文致力于比较 FAPI PET 和[18F]氟脱氧葡萄糖（FDG）PET 在评估胰腺癌原发肿瘤、淋巴结和远处转移中的诊断效果：在本综述中，我们对截至 2023 年 9 月 18 日发表在 PubMed 和 Web of Science 数据库中的研究进行了系统检索。所有纳入的研究均使用放射性核素标记的 FAPI 和 FDG 作为 PET 诊断示踪剂，以评估它们在胰腺癌患者中的适用性：FAPI PET 成像组在检测原发病灶（1.000，[95% CI：0.999-1.000]）、淋巴结转移（0.624 [95% CI：0.391-0.834]）和远处转移（0.965[95%CI：0.804-1.000]]）相比，胰腺癌FDG PET成像组（分别为0.889[95%CI：0.788-0.966]、0.373[95%CI：0.163-0.606]和0.889[95%CI：0.689-0.999]）。此外，对于原发病灶，FAPI PET 成像的最大标准化摄取值（SUVmax）明显高于 FDG 成像（平均差（MD）= 7.51，95% CI：5.34-9.67）：结论：与[18F]FDG PET/CT 相比，FAPI PET 成像显示出更高的灵敏度和 SUVmax。该方法可有效用于胰腺癌的评估：成纤维细胞活化蛋白抑制剂 PET 可替代[18F]FDG 评估原发性胰腺癌、淋巴结转移和远处转移：要点：成纤维细胞活化蛋白抑制剂（FAPI）正电子发射计算机断层显像与 FDG 正电子发射计算机断层显像在评估胰腺癌方面进行了比较。多种放射性标记的 FAPI 变体在胰腺癌诊断中显示出良好的效果。FAPI PET 成像能有效帮助临床医生对胰腺癌进行诊断和分期。
Performance of fibroblast activating protein inhibitor PET imaging for pancreatic neoplasms assessment: a systematic review and meta-analysis.
Background: Recent studies have shown the potential of fibroblast activating protein inhibitor (FAPI) PET imaging for pancreatic cancer assessment.
Purpose: This article is dedicated to comparing the diagnostic efficacy of FAPI PET and [18F]fluorodeoxyglucose (FDG) PET in the evaluation of primary tumors, lymph nodes, and distant metastases in pancreatic cancer.
Methods: In this review, we conducted a systematic search of studies published in PubMed and Web of Science databases up to September 18, 2023. All included studies used radionuclide labeled FAPI and FDG as PET diagnostic tracers to evaluate their applicability in patients with pancreatic cancer.
Results: The FAPI PET imaging group showed significantly higher sensitivity in the detection of primary lesions (1.000, [95% CI: 0.999-1.000]), lymph node metastases (0.624 [95% CI: 0.391-0.834]) and distant metastatic (0.965 [95% CI: 0.804-1.000]) in pancreatic cancer compared to the FDG PET imaging group (0.889 [95% CI: 0.788-0.966], 0.373 [95% CI: 0.163-0.606] and 0.889 [95% CI: 0.689-0.999], respectively). Furthermore, the maximum standardized uptake value (SUVmax) in FAPI PET imaging is significantly higher than that in FDG imaging for primary lesions (mean difference (MD) = 7.51, 95% CI: 5.34-9.67).
Conclusion: Compared with [18F]FDG PET/CT, FAPI PET imaging showed higher sensitivity, SUVmax. This method can be effectively utilized for the evaluation of pancreatic cancer.
Clinical relevance statement: Fibroblast activating protein inhibitor PET may be a better alternative to [18F]FDG in evaluating primary pancreatic cancer, lymph node metastases, and distant metastases.
Key points: Fibroblast activating protein inhibitor (FAPI) PET is compared with FDG PET for evaluating pancreatic cancer. Multiple radiolabeled FAPI variants have shown promising results in the diagnosis of pancreatic cancer. FAPI PET imaging effectively helps clinicians diagnose and stage pancreatic cancer.
期刊介绍：
European Radiology (ER) continuously updates scientific knowledge in radiology by publication of strong original articles and state-of-the-art reviews written by leading radiologists. A well balanced combination of review articles, original papers, short communications from European radiological congresses and information on society matters makes ER an indispensable source for current information in this field.
This is the Journal of the European Society of Radiology, and the official journal of a number of societies.
From 2004-2008 supplements to European Radiology were published under its companion, European Radiology Supplements, ISSN 1613-3749.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
